drugset
drugset / Trial / NCT06806982

A Study of VRN101099 in Patients With HER2-Positive Solid Tumors

NCT06806982 ↗

Phase 1 Recruiting 72 enrolled Voronoi, Inc
NaSingle-groupOpen-labelTreatment

Summary

This FIH open-label study aims to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and antitumor effect of VRN101099 in patients with HER2-positive solid tumors for whom no standard therapies are available.

Timeline

Start
2025-02-17
Primary completion
2026-05-01
Completion
2027-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject VRN101099 Unknown 80 mg Oral
Subject VRN101099 Unknown 160 mg Oral
Subject VRN101099 Unknown 240 mg Oral
Subject VRN101099 Unknown 320 mg Oral
Subject VRN101099 Unknown 400 mg Oral
Subject VRN101099 Unknown 480 mg Oral

Indications

carcinoma